3rd Quarter - Report

SLC HEALTH STRATEGIES, LLC for NOVO NORDISK PHARMACEUTICALS, INC.

Firm
Client
Income
$22,500
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

HR 1192/S 586 National Diabetes Clinical Care Commission Act of 2015 S 1695 / HR 3020 -- National Diabetes Prevention Program funding as part of the Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act for FY 2016 Implementation of the Affordable Care and Health Care & Education Affordability Reconciliation Act of 2010 (PL 111-148 and 111-152); diabetes screening Human growth hormone, obesity and rare disease matters Legislation (no bill number yet) regarding private not-for-profit foundations paying for health exchange premiums and cost sharing for certain individuals.

LobbyistCovered position, as disclosed
SHARON COHEN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1192 (114th), H.R. 3020 (114th)

Medicare/Medicaid MMM

HR 2 - Medicare Access and CHIP Reauthorization Act of 2015 PL 114-10 -- Medicare Access and CHIP Reauthorization Act of 2015 S 1509 / HR 2404-- Treat and Reduce Obesity Act of 2015 -- Medicare coverage of FDA-approved obesity medications HR 6 - 21st Century Cures Act In the above measures, specifically potential pharmaceutical reimbursement cuts as potential offsets including potential changes to Part D as well as Medicare coverage for FDA-approved obesity medications.

LobbyistCovered position, as disclosed
SHARON COHEN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 6 (114th), H.R. 2404 (114th), H.R. 2 (114th)

Budget/Appropriations BUD

H. Con. Res. 27, "Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025" S. Con. Res. 11/H.Con.Res. 27, "An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025." In the above, specifically potential pharmaceutical reimbursement cuts as potential offsets AND potential inclusion of Medicare coverage of FDA-approved obesity drugs. S 1695 /HR3020 --FY 2016 Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act, specifically NDPP funding. HR 3660 Preventive Health Savings Act HR 716/H.J.Res 61 Continuing Appropriation through 12/11/15 (PL114-53).

LobbyistCovered position, as disclosed
SHARON COHEN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 3660 (114th), H.J.Res. 61 (114th), H.R. 3020 (114th), H.R. 716 (114th), S.Con.Res. 11 (114th), H.Con.Res. 27 (114th)

Pharmacy PHA

HR 6 - 21st Century Cures Act FDA issues regarding biosimilar products; 340B program matters

LobbyistCovered position, as disclosed
SHARON COHEN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 6 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.